“IONIS FB LRX- Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Geographic Atrophy in 7 Major Markets. A detailed picture of the IONIS FB LRX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
IONIS-FB-LRx is a Generation 2+ ligand-conjugated antisense (LICA) drug designed to reduce the production of complement factor B (FB). Genetic association studies have shown that overaction of this cascade has been associated with the development of several complement-mediated diseases, including IgA nephropathy (IgAN). FB, a key regulatory protein, is produced predominately in the liver and circulates at high levels throughout the vascular system, including in the kidney.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of IONIS FB LRX in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of IONIS FB LRX covering trial interventions, trial conditions, trial status, start and completion dates.
1. Drug Overview
1.1. Product Detail
1.2. Mechanism of Action
1.3. Dosage and Administration
1.4. Research and development activity
1.4.1. Clinical Development
1.4.2. Safety and Efficacy
1.5. Other Development Activities
2. Market Assesment
2.1. 7MM Market Analysis
2.2. The United States Market
2.3. Germany Market
2.4. France Market
2.5. Italy Market
2.6. Spain Market
2.7. United Kingdom Market
2.8. Japan Market
3. SWOT Analysis
4. Analyst Views
5. Market Competitors
6. Other Emerging Therapies
7. Appendix
8. Report Purchase Options
List of Table
Table 1 IONIS FB LRX, Description
Table 2 IONIS FB LRX, Clinical Trial Description
Table 3 IONIS FB LRX, 7MM Market Size from 2020 to 2030 (in Million USD)
Table 4 Market Competitors
Table 5 Other Emerging Therapies
List of Figure
Figure 1 The Development Timeline of IONIS FB LRX
Figure 2 Patent Details, IONIS FB LRX
Figure 3 IONIS FB LRX, 7MM Market Size from 2020 to 2030 (in Million USD)
Figure 4 IONIS FB LRX, US Market Size from 2020 to 2030 (in Millions USD)
Figure 5 IONIS FB LRX, EU5 Market Size from 2020 to 2030 (in Millions USD)
Figure 6 IONIS FB LRX, Japan Market Size from 2020 to 2030 (in Millions USD)
